Top

Current Heart Failure Reports

Published in:

27-03-2024 | Ventricular Tachycardia | Review

Catheter Ablation of Ventricular Tachycardia in Ischemic Heart Disease: What Is Known and New Perspectives

Authors: Pasquale Valerio Falzone, Sara Vazquez-Calvo, Ivo Roca-Luque

Published in: Current Heart Failure Reports | Issue 3/2024

Abstract

Purpose of the Review

This review aims to evaluate current evidence regarding ventricular tachycardia ablation in patients with ischemic heart disease and explore novel approaches currently developing to improve procedural and long-term outcomes.

Recent Findings

Recently published trials (PARTITA, PAUSE-SCD, and SURVIVE-VT) have demonstrated the prognostic benefit of prophylactic ventricular tachycardia ablation compared to current clinical practice. Advanced cardiac imaging provides a valuable pre-procedural evaluation of the arrhythmogenic substrate, identifying ablation targets non-invasively. Advanced cardiac mapping techniques allow to better characterize arrhythmogenic substrate during ablation procedure. Emerging technologies like pulsed field ablation and ultra-low temperature cryoablation show promise in ventricular tachycardia ablation.

Summary

Advancements in mapping techniques, ablation technologies, and pre-procedural cardiac imaging offer promise for improving ventricular tachycardia ablation outcomes in ischemic heart disease.

Townsend N, Kazakiewicz D, Lucy Wright F, Timmis A, Huculeci R, Torbica A, Gale CP, Achenbach S, Weidinger F, Vardas P. Epidemiology of cardiovascular disease in Europe. Nat Rev Cardiol. 2022;19:133–43.PubMedCrossRef

Danchin N, Puymirat E, Simon T. The (possibly) deceptive figures of decreased coronary heart disease mortality in Europe. Eur Heart J. 2013;34:3014–6.PubMedCrossRef

Ndrepepa G, Mehilli J, Schwaiger M, Schühlen H, Nekolla S, Martinoff S, Schmitt C, Dirschinger J, Schömig A, Kastrati A. Prognostic value of myocardial salvage achieved by reperfusion therapy in patients with acute myocardial infarction. J Nucl Med. 2004;45(5):725–9

Ndrepepa G. Improving myocardial injury, infarct size, and myocardial salvage in the era of primary PCI for STEMI. Coron Artery Dis. 2015;26:341–55.PubMedCrossRef

Lo R, Chia KKM, Hsia HH. Ventricular tachycardia in ischemic heart disease. Card Electrophysiol Clin. 2017;9:25–46.PubMedCrossRef

Wijnmaalen AP, Schalij MJ, Von Der Thüsen JH, Klautz RJM, Zeppenfeld K. Early reperfusion during acute myocardial infarction affects ventricular tachycardia characteristics and the chronic electroanatomic and histological substrate. Circulation. 2010;121:1887–95.PubMedCrossRef

Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43:3997–4126.PubMedCrossRef

Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or animplantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225–37. https://doi.org/10.1056/NEJMoa043399. Erratum in: N Engl J Med. 2005;352(20):2146

Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML; Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877–83. https://doi.org/10.1056/NEJMoa013474

10.

Kamphuis HCM, de Leeuw JR, Derksen R, Hauer RNW, Winnubst JAM. Implantable cardioverter defibrillator recipients: quality of life in recipients with and without ICD shock delivery: A prospective study. Europace. 2003;5:381–9.PubMedCrossRef

11.

Moss AJ, Greenberg H, Case RB, Zareba W, Hall WJ, Brown MW, Daubert JP, McNitt S, Andrews ML, Elkin AD. Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation. 2004;110:3760–5.PubMedCrossRef

12.

Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324(12):781–8. https://doi.org/10.1056/NEJM199103213241201

13.

Santangeli P, Muser D, Maeda S, Filtz A, Zado ES, Frankel DS, Dixit S, Epstein AE, Callans DJ, Marchlinski FE. Comparative effectiveness of antiarrhythmic drugs and catheter ablation for the prevention of recurrent ventricular tachycardia in patients with implantable cardioverter-defibrillators: a systematic review and meta-analysis of randomized controlled trials. Heart Rhythm. 2016;13:1552–9.PubMedCrossRef

14.

Amoni M, Dries E, Ingelaere S, Vermoortele D, Roderick HL, Claus P, Willems R, Sipido KR. Ventricular arrhythmias in ischemic cardiomyopathy—new avenues for mechanism-guided treatment. Cells. 2021. https://doi.org/10.3390/cells10102629.CrossRefPubMedPubMedCentral

15.

Richardson WJ, Clarke SA, Alexander Quinn T, Holmes JW. Physiological implications of myocardial scar structure. Compr Physiol. 2015;5:1877–909.PubMedPubMedCentralCrossRef

16.

Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation. 1977;56(5):786–94. https://doi.org/10.1161/01.cir.56.5.786

17.

Fenoglio JJ, Pham TD, Harken AH, Horowitz LN, Josephson ME, Wit AL, Fenoglio JF. Recurrent sustained ventricular tachycardia: structure and ultrastructure of subendocardial regions in which tachycardia originates. Circulation. 1983;68(3):518–33. https://doi.org/10.1161/01.cir.68.3.518.

18.

Meja Lopez E, Malhotra R. Ventricular tachycardia in structural heart disease. J Innov Cardiac Rhythm Manag. 2019;10:3762–73.CrossRef

19.

Guandalini GS, Liang JJ, Marchlinski FE. Ventricular tachycardia ablation: past, present, and future perspectives. JACC Clin Electrophysiol. 2019;5:1363–83.PubMedCrossRef

20.

Marchlinski FE, Callans DJ, Gottlieb CD, Zado E. Linear ablation lesions for control of unmappable ventricular tachycardia in patients with ischemic and nonischemic cardiomyopathy. Circulation. 2000;101(11):1288–96. https://doi.org/10.1161/01.cir.101.11.1288.

21.

Hsia HH, Callans DJ, Marchlinski FE. Characterization of endocardial electrophysiological substrate in patients with nonischemic cardiomyopathy and monomorphic ventricular tachycardia. Circulation. 2003;108:704–10.PubMedCrossRef

22.

Jaïs P, Maury P, Khairy P, et al. Elimination of local abnormal ventricular activities : a new end point for substrate modification in patients with scar-related ventricular tachycardia. Circulation. 2012;125:2184–96.PubMedCrossRef

23.

Arenal A, Glez-Torrecilla E, Ortiz M, Villacastín J, Fdez-Portales J, Sousa E, del Castillo S, Perez de Isla L, Jimenez J, Almendral J. Ablation of electrograms with an isolated, delayed component as treatment of unmappable monomorphic ventricular tachycardias in patients with structural heart disease. J Am Coll Cardiol. 2003;41(1):81–92. https://doi.org/10.1016/s0735-1097(02)02623-2.

24.

Berruezo A, Fernández-Armenta J, Andreu D, et al. Scar dechanneling. Circ Arrhythm Electrophysiol. 2015;8:326–36.PubMedCrossRef

25.

Di Biase L, Santangeli P, Burkhardt DJ, et al. Endo-epicardial homogenization of the scar versus limited substrate ablation for the treatment of electrical storms in patients with ischemic cardiomyopathy. J Am Coll Cardiol. 2012;60:132–41.PubMedCrossRef

26.

Tzou WS, Frankel DS, Hegeman T, Supple GE, Garcia FC, Santangeli P, Katz DF, Sauer WH, Marchlinski FE. Core isolation of critical arrhythmia elements for treatment of multiple scar-based ventricular tachycardias. Circ Arrhythm Electrophysiol. 2015;8:353–61.PubMedCrossRef

27.

Biase L Di, David Burkhardt J, Lakkireddy D, et al. Ablation of stable VTs versus substrate ablation in ischemic cardiomyopathy the VISTA randomized multicenter trial. J Am Coll Cardiol. 2015;66(25):2872–2882. https://doi.org/10.1016/j.jacc.2015.10.026.

28.

Vázquez-Calvo S, Roca-Luque I, Porta-Sánchez A. Ventricular tachycardia ablation guided by functional substrate mapping: practices and outcomes. J Cardiovasc Dev Dis. 2022. https://doi.org/10.3390/jcdd9090288.CrossRefPubMedPubMedCentral

29.

Irie T, Yu R, Bradfield JS, et al. Relationship between sinus rhythm late activation zones and critical sites for scar-related ventricular tachycardia. Circ Arrhythm Electrophysiol. 2015;8:390–9.PubMedPubMedCentralCrossRef

30.

Aziz Z, Shatz D, Raiman M, et al. Targeted ablation of ventricular tachycardia guided by wavefront discontinuities during sinus rhythm: a new functional substrate mapping strategy. Circulation. 2019;140:1383–97.PubMedCrossRef

31.

Jackson N, Gizurarson S, Viswanathan K, et al. Decrement evoked potential mapping: basis of a mechanistic strategy for ventricular tachycardia ablation. Circ Arrhythm Electrophysiol. 2015;8:1433–42.PubMedCrossRef

32.

Porta-Sánchez A, Jackson N, Lukac P, et al. Multicenter study of ischemic ventricular tachycardia ablation with decrement-evoked potential (DEEP) mapping with extra stimulus. JACC Clin Electrophysiol. 2018;4:307–15.PubMedCrossRef

33.

Srinivasan NT, Garcia J, Schilling RJ, et al. Multicenter study of dynamic high-density functional substrate mapping improves identification of substrate targets for ischemic ventricular tachycardia ablation. JACC Clin Electrophysiol. 2020;6:1783–93.PubMedPubMedCentralCrossRef

34.

de Riva M, Naruse Y, Ebert M, et al. Targeting the hidden substrate unmasked by right ventricular extrastimulation improves ventricular tachycardia ablation outcome after myocardial infarction. JACC Clin Electrophysiol. 2018;4:316–27.PubMedCrossRef

35.

Acosta J, Andreu D, Penela D, et al. Elucidation of hidden slow conduction by double ventricular extrastimuli: a method for further arrhythmic substrate identification in ventricular tachycardia ablation procedures. Europace. 2018;20:337–46.PubMedCrossRef

36.

Sapp JL, Wells GA, Parkash R, et al. Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs. N Engl J Med. 2016;375:111–21.PubMedCrossRef

37.

Lima da Silva G, Nunes-Ferreira A, Cortez-Dias N, de Sousa J, Pinto FJ, Caldeira D. Radiofrequency catheter ablation of ventricular tachycardia in ischemic heart disease in light of current practice: a systematic review and meta-analysis of randomized controlled trials. J Interv Cardiac Electrophysiol. 2020;59:603–16.CrossRef

38.

Lee DS, Gona P, Albano I, Larson MG, Benjamin EJ, Levy D, Kannel WB, Vasan RS. A systematic assessment of causes of death after heart failure onset in the community. Circ Heart Fail. 2011;4:36–43.PubMedCrossRef

39.

Calkins H, Epstein A, Packer D, et al. Catheter ablation of ventricular tachycardia in patients with structural heart disease using cooled radiofrequency energy results of a prospective multicenter study. Cooled RF Multi Center Investigators Group. J Am Coll Cardiol. 2000;35(7):1905–14. https://doi.org/10.1016/s0735-1097(00)00615-x.

40.

Stevenson WG, Wilber DJ, Natale A, et al. Irrigated radiofrequency catheter ablation guided by electroanatomic mapping for recurrent ventricular tachycardia after myocardial infarction the multicenter thermocool ventricular tachycardia ablation trial. Circulation. 2008;118:2773–82.PubMedCrossRef

41.

Reddy VY, Reynolds MR, Neuzil P, et al. Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med. 2007;357(26):2657–65. https://doi.org/10.1056/NEJMoa065457.

42.

Kuck KH, Schaumann A, Eckardt L, Willems S, Ventura R, Delacrétaz E, Pitschner HF, Kautzner J, Schumacher B, Hansen PS. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. Lancet. 2010;375:31–40.PubMedCrossRef

43.

Kuck KH, Tilz RR, Deneke T, Hoffmann BA, Ventura R, Hansen PS, Zarse M, Hohnloser SH, Kautzner J, Willems S. Impact of substrate modification by catheter ablation on implantable cardioverter-defibrillator interventions in patients with unstable ventricular arrhythmias and coronary artery disease: Results from the multicenter randomized controlled SMS (Substrate Modification Study). Circ Arrhythm Electrophysiol. 2017. https://doi.org/10.1161/CIRCEP.116.004422.CrossRefPubMed

44.

Willems S, Tilz RR, Steven D, et al. Preventive or deferred ablation of ventricular tachycardia in patients with ischemic cardiomyopathy and implantable defibrillator (Berlin VT): a multicenter randomized trial. Circulation. 2020;141(13):1057–1067. https://doi.org/10.1161/CIRCULATIONAHA.119.043400.

45.

•• Della Bella P, Baratto F, Vergara P, et al. Does timing of ventricular tachycardia ablation affect prognosis in patients with an implantable cardioverter defibrillator? Results from the multicenter randomized PARTITA trial. Circulation. 2022;145:1829–38. First trial to demonstrate a prognostic benefit of VT ablation in ischemic heart disease.PubMedCrossRef

46.

•• Tung R, Xue Y, Chen M, et al. First-line catheter ablation of monomorphic ventricular tachycardia in cardiomyopathy concurrent with defibrillator implantation: the PAUSE-SCD randomized trial. Circulation. 2022;145:1839–49. Another trial demonstrated a prognostic benefit of VT ablation in Ischemic and No-Ischemic heart disease.PubMedCrossRef

47.

•• Arenal Á, Ávila P, Jiménez-Candil J, et al. Substrate ablation vs antiarrhythmic drug therapy for symptomatic ventricular tachycardia. J Am Coll Cardiol. 2022;79:1441–53. Another trial demonstrated a prognostic benefit of VT ablation in Ischemic and heart disease.PubMedCrossRef

48.

Roca-Luque I, Mont-Girbau L. Cardiac Magnetic Resonance for Ventricular Tachycardia Ablation and Risk Stratification. Front Cardiovasc Med. 2022. https://doi.org/10.3389/fcvm.2021.797864.CrossRefPubMedPubMedCentral

49.

Kim RJ, Fieno DS, Todd B, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation. 1999;100(19):1992–2002. https://doi.org/10.1161/01.cir.100.19.1992.

50.

Perez-David E, Arenal Á, Rubio-Guivernau JL, et al. Noninvasive identification of ventricular tachycardia-related conducting channels using contrast-enhanced magnetic resonance imaging in patients with chronic myocardial infarction: Comparison of signal intensity scar mapping and endocardial voltage mapping. J Am Coll Cardiol. 2011;57:184–94.PubMedCrossRef

51.

Andreu D, Berruezo A, Ortiz-Pérez JT, et al. Integration of 3D electroanatomic maps and magnetic resonance scar characterization into the navigation system to guide ventricular tachycardia ablation. Circ Arrhythm Electrophysiol. 2011;4:674–83.PubMedCrossRef

52.

• Sánchez-Somonte P, Quinto L, Garre P, et al. Scar channels in cardiac magnetic resonance to predict appropriate therapies in primary prevention. Heart Rhythm. 2021;18:1336–43. Demonstration of how CMR could predict appropriate therapies in primart prevention.PubMedCrossRef

53.

• Quinto L, Sanchez P, Alarcón F, et al. Cardiac magnetic resonance to predict recurrences after ventricular tachycardia ablation: septal involvement, transmural channels, and left ventricular mass. Europace. 2021;23:1437–45. Demonstration of how CMR could predict recurrence after VT ablation.PubMedCrossRef

54.

• Sanchez-Somonte P, Garre P, Vázquez-Calvo S, et al. Scar conducting channel characterization to predict arrhythmogenicity during ventricular tachycardia ablation. Europace. 2023;25:989–99. Pre-procedural CMR substrate evaluation could predict the arrhythmogenity of a determined conductive channel during VT ablation.PubMedPubMedCentralCrossRef

55.

•• Soto-Iglesias D, Penela D, Jáuregui B, et al. Cardiac magnetic resonance-guided ventricular tachycardia substrate ablation. JACC Clin Electrophysiol. 2020;6:436–47. CMR substrate evaluation could be useful to aid and guide VT ablation.PubMedCrossRef

56.

• Vázquez-Calvo S, Casanovas JM, Garre P, et al. Evolution of deceleration zones during ventricular tachycardia ablation and relation with cardiac magnetic resonance. JACC Clin Electrophysiol. 2023. https://doi.org/10.1016/j.jacep.2022.12.015. New deceleration zones could appear after the first ablation set, especially among CMR identified channels.CrossRefPubMed

57.

Singh A, Kawaji K, Goyal N, et al. Feasibility of cardiac magnetic resonance wideband protocol in patients with implantable cardioverter defibrillators and its utility for defining scar. Am J Cardiol. 2019;123:1329–35.PubMedPubMedCentralCrossRef

58.

Conte E, Mushtaq S, Carbucicchio C, et al. State of the art paper: cardiovascular CT for planning ventricular tachycardia ablation procedures. J Cardiovasc Comput Tomogr. 2021;15:394–402.PubMedCrossRef

59.

Gerber BL, Belge B, Legros GJ, Lim P, Poncelet A, Pasquet A, Gisellu G, Coche E, Vanoverschelde JLJ. Characterization of acute and chronic myocardial infarcts by multidetector computed tomography: comparison with contrast-enhanced magnetic resonance. Circulation. 2006;113:823–33.PubMedCrossRef

60.

Di Cesare E, Carbone I, Carriero A, et al. Indicazioni cliniche per l’utilizzo della tomografia computerizzata del cuore. A cura del gruppo di lavoro della Sezione di Cardio-Radiologia della Società Italiana di Radiologia Medica (SIRM). Radiologia Medica. 2012;117:901–38.PubMed

61.

Palmisano A, Vignale D, Benedetti G, Del Maschio A, De Cobelli F, Esposito A. Late iodine enhancement cardiac computed tomography for detection of myocardial scars: impact of experience in the clinical practice. Radiologia Medica. 2020;125:128–36.PubMedCrossRef

62.

Takigawa M, Duchateau J, Sacher F, et al. Are wall thickness channels defined by computed tomography predictive of isthmuses of postinfarction ventricular tachycardia? Heart Rhythm. 2019;16:1661–8.PubMedCrossRef

63.

Qiu J, Dai M, Bai Y, Chen G. Potential application of pulsed field ablation in ventricular arrhythmias. Medicina (Lithuania). 2023. https://doi.org/10.3390/medicina59040723.

64.

Verma A, Haines DE, Boersma LV, et al. Pulsed field ablation for the treatment of atrial fibrillation: PULSED AF pivotal trial. Circulation. 2023. https://doi.org/10.1161/circulationaha.123.063988.CrossRefPubMedPubMedCentral

65.

Ekanem E, Reddy VY, Schmidt B, et al. Multi-national survey on the methods, efficacy, and safety on the post-approval clinical use of pulsed field ablation (MANIFEST-PF). Europace. 2022;24:1256–66.PubMedPubMedCentralCrossRef

66.

Neven K, Van Driel V, Van Wessel H, Van Es R, Doevendans PA, Wittkampf F. Myocardial lesion size after epicardial electroporation catheter ablation after subxiphoid puncture. Circ Arrhythm Electrophysiol. 2014;7:728–33.PubMedCrossRef

67.

Koruth JS, Kuroki K, Iwasawa J, Viswanathan R, Brose R, Buck ED, Donskoy E, Dukkipati SR, Reddy VY. Endocardial ventricular pulsed field ablation: a proof-of-concept preclinical evaluation. Europace. 2020;22:434–9.PubMedCrossRef

68.

Il IS, Higuchi S, Lee A, Stillson C, Buck E, Morrow B, Schenider K, Speltz M, Gerstenfeld EP. Pulsed field ablation of left ventricular myocardium in a swine infarct model. JACC Clin Electrophysiol. 2022;8:722–31.CrossRef

69.

•• Ouss A, van Stratum L, van der Voort P, Dekker L. First in human pulsed field ablation to treat scar-related ventricular tachycardia in ischemic heart disease: a case report. J Interv Card Electrophysiol. 2022. https://doi.org/10.1007/s10840-022-01407-6. First in human Pulsed Field ablation realized in scar-related VT ablation.CrossRefPubMedPubMedCentral

70.

Lozano-Granero C, Hirokami J, Franco E, Tohoku S, Matía-Francés R, Schmidt B, Hernández-Madrid A, Zamorano Gómez JL, Moreno J, Chun J. Case series of ventricular tachycardia ablation with pulsed-field ablation: pushing technology further (into the ventricle). JACC Clin Electrophysiol. 2023. https://doi.org/10.1016/j.jacep.2023.03.024.CrossRefPubMed

71.

Kuck KH, Brugada J, Fürnkranz A, et al. Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation. J Cardiopulm Rehabil Prev. 2016;36:393–4.

72.

Rivera S, De La Paz RM, Tomas L, et al. Results of cryoenergy and radiofrequency-based catheter ablation for treating ventricular arrhythmias arising from the papillary muscles of the left ventricle, guided by intracardiac echocardiography and image integration. Circ Arrhythm Electrophysiol. 2016. https://doi.org/10.1161/CIRCEP.115.003874.CrossRefPubMed

73.

De Potter T, Klaver M, Babkin A, Iliodromitis K, Hocini M, Cox J, Boersma L. Ultra-low temperature cryoablation for atrial fibrillation: primary outcomes for efficacy and safety: the Cryocure-2 study. JACC Clin Electrophysiol. 2022;8:1034–9.PubMedCrossRef

74.

Klaver MN, De Potter TJR, Iliodromitis K, Babkin A, Cabrita D, Fabbricatore D, Boersma LVA. Ultralow temperature cryoablation using near-critical nitrogen for cavotricuspid isthmus-ablation, first-in-human results. J Cardiovasc Electrophysiol. 2021;32:2025–32.PubMedPubMedCentralCrossRef

75.

Bourier F, Takigawa M, Lam A, et al. Ultralow temperature cryoablation: safety and efficacy of preclinical atrial and ventricular lesions. J Cardiovasc Electrophysiol. 2021;32:570–7.PubMedCrossRef

76.

•• De Potter T, Balt JC, Boersma L, Sacher F, Neuzil P, Reddy V, Grigorov I, Verma A. First-in-human experience with ultra-low temperature cryoablation for monomorphic ventricular tachycardia. JACC Clin Electrophysiol. 2023. https://doi.org/10.1016/j.jacep.2022.11.017. First in human use of ULTC to treat monomorphic ventricular tachycardia.CrossRefPubMed

77.

Vázquez-Calvo S, Roca-Luque I, Althoff TF. Management of ventricular arrhythmias in heart failure. Curr Heart Fail Rep. 2023;20:237–53.PubMedCrossRef

Title: Catheter Ablation of Ventricular Tachycardia in Ischemic Heart Disease: What Is Known and New Perspectives
Authors: Pasquale Valerio Falzone
Sara Vazquez-Calvo
Ivo Roca-Luque
Publication date: 27-03-2024
Publisher: Springer US
Keyword: Ventricular Tachycardia
Published in: Current Heart Failure Reports / Issue 3/2024
Print ISSN: 1546-9530
Electronic ISSN: 1546-9549
DOI: https://doi.org/10.1007/s11897-024-00656-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of the Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 3/2024

Relevance of Cardiovascular Exercise in Cancer and Cancer Therapy-Related Cardiac Dysfunction

Non-Coding Ribonucleic Acids as Diagnostic and Therapeutic Targets in Cardiac Fibrosis

Putting More Weight on Obesity Trials in Heart Failure

Economic Considerations of Cardiovascular Implantable Electronic Devices for The Treatment of Heart Failure

Cellular Alterations in Immune Checkpoint Inhibitor Therapy-Related Cardiac Dysfunction

Pregnancy, Reproductive Factors, and Female Heart Failure Risk and Outcomes

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage